Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone in chronic subdural hematoma
NCT02938468Phase 3Unknown
- Sponsor
- University of Calgary
- Start
- Sep 2016
- Primary completion
- Sep 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexamethasone in chronic subdural hematoma (CSDH) (2 arms), sponsored by University of Calgary. Primary endpoint: Failure rates at 3 months. Status: unknown.
02
Drugs
dexamethasone
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT02938468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02938468.